Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(4.75)
# 126
Out of 5,133 analysts
24
Total ratings
66.67%
Success rate
50.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OVID Ovid Therapeutics | Initiates: Buy | $3 | $1.65 | +81.82% | 1 | Dec 11, 2025 | |
| CING Cingulate | Maintains: Buy | $17 → $16 | $4.92 | +225.20% | 4 | Nov 19, 2025 | |
| PYPD PolyPid | Maintains: Buy | $10 → $9 | $4.41 | +104.08% | 3 | Nov 13, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $12 → $13 | $24.79 | -47.56% | 3 | Nov 12, 2025 | |
| RNA Avidity Biosciences | Initiates: Buy | $62 | $72.43 | -14.40% | 1 | Sep 17, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Reiterates: Buy | $7 → $3 | $0.36 | +745.07% | 2 | Aug 18, 2025 | |
| LGVN Longeveron | Maintains: Buy | $10 → $3 | $0.55 | +447.25% | 2 | Aug 15, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 → $6 | $2.23 | +169.06% | 3 | Aug 13, 2025 | |
| CRVO CervoMed | Reiterates: Buy | $20 → $16 | $7.52 | +112.77% | 4 | Aug 12, 2025 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $10.46 | +177.25% | 1 | Dec 5, 2024 |
Ovid Therapeutics
Dec 11, 2025
Initiates: Buy
Price Target: $3
Current: $1.65
Upside: +81.82%
Cingulate
Nov 19, 2025
Maintains: Buy
Price Target: $17 → $16
Current: $4.92
Upside: +225.20%
PolyPid
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $4.41
Upside: +104.08%
Capricor Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $24.79
Upside: -47.56%
Avidity Biosciences
Sep 17, 2025
Initiates: Buy
Price Target: $62
Current: $72.43
Upside: -14.40%
Reviva Pharmaceuticals Holdings
Aug 18, 2025
Reiterates: Buy
Price Target: $7 → $3
Current: $0.36
Upside: +745.07%
Longeveron
Aug 15, 2025
Maintains: Buy
Price Target: $10 → $3
Current: $0.55
Upside: +447.25%
Gain Therapeutics
Aug 13, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.23
Upside: +169.06%
CervoMed
Aug 12, 2025
Reiterates: Buy
Price Target: $20 → $16
Current: $7.52
Upside: +112.77%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $10.46
Upside: +177.25%